Business
Easton Pharmaceuticals Provides Update on Initiatives Towards Its Cancer Drug "Xilive" and Its Mexican Government Regulatory Filing Submission for "Viorra"
Easton Pharmaceuticals Provides Update on Initiatives Towards Its Cancer Drug "Xilive" and Its Mexican Government Regulatory Filing Submission for "Viorra".
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals Provides Update on Initiatives Towards Its Cancer Drug \"Xilive\" and Its Mexican Government Regulatory Filing Submission for \"Viorra\"\n \n \nEaston Pharmaceuticals Provides Update on Initiatives Towards Its Cancer Drug \"Xilive\" and Its Mexican Government Regulatory Filing Submission for \"Viorra\"\n \n TORONTO, ON--(Marketwired - Dec 11, 2013) - Easton Pharmaceuticals (OTC: EAPH), a specialty pharmaceutical company that owns, designs, develops, and markets an array of topically-delivered drugs and therapeutic healthcare products provides update towards its 2 main initiatives, its minority ownership interest for its early stage cancer drug \"Xilive\" and on its Mexican government regulatory filing For Its \"Viorra\" product.\n The Company is attempting to allocate its financial resources in the most cost effective manner possible. As a result of the company's recent purchase of its minority ownership interest in its early stage Cancer Drug \"Xilive\" and the positive feedback received, Easton Pharmaceuticals has shifted its main focus towards \"Xilive\" and initiating some form of early stage clinical trial testing program as well as continuing with its government approval process for \"Viorra\" in Mexico and other Latin American countries. Easton Pharmaceuticals has initiated discussions with both in-house consultants as well as third parties who have prior knowledge and experience with bringing such a testing program forward with both the FDA and within other countries such as Mexico and Canada. Due to cost and regulatory reasons, the Company and the current majority owners of its cancer drug \"Xilive\" believe the best course of action for \"Xilive\" is to attempt to initially enter into some form of testing protocol outside of the United States prior to entering into more expensive FDA recognized clinical trials in the United States. The Company believes its best to initially focus towards other jurisdictions such as Mexico, Canada, Italy, Germany and various other countries including China where costs are deemed greatly reduced and regulations are considered quicker, much less stringent and more favorable towards allowing the use of early stage cancer drugs such as \"Xilive\" to be utilized on prospective Cancer patients in controlled trials. Although certain states in the United States a...